Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- With Growing Competition from Foreign Drug Makers, Takeda Interested in Product Tie-ups: President Hasegawa
March 8, 2013
- Yakult Enters Biosimilars Business, Ties Up with UMN and API
March 7, 2013
- Novartis Withdraws Application for Glivec for PAH in Japan
March 7, 2013
- Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
- Sawai's New Plant Starts Operation, Raising Annual Production Capacity to 8 Billion Tablets
March 6, 2013
- Nichi-Iko's New Factory Completed in Toyama, Production Capacity to Reach 7-8 Billion Tablets a Year
March 6, 2013
- DSP to Merge Its Clinical Development Functions with US Subsidiary’s
March 6, 2013
- Ranbaxy Resumes Production of Atorvastatin at US Plant
March 6, 2013
- 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
- Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
- 3-Drug H. pylori Eradication Therapies to Get Further Indication for Chronic Gastritis; Big Boost to PPI Market Expected
March 5, 2013
- Daiichi Sankyo to Set Up Biologics Oversight Function within R&D Division in Order to Enhance Biopharmaceutical Research Level
March 5, 2013
- Teva Pharma, Nippon Kayaku Receive Approval of Japan’s Second G-CSF Biosimilar
March 5, 2013
- Announcement: 6th annual Marketing Excellence Japan 2013 – Hilton Tokyo, May 14 – 15
March 4, 2013
- Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
- Extra Concurrent-Use Indications Approved for DPP-4 Inhibitor Equa: Novartis
March 4, 2013
- Merck Serono Appoints Koichi Katsura as Head of R&D Japan
March 4, 2013
- Abilify Once-Monthly Injection Approved in US: Otsuka
March 4, 2013
- ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
- Astellas to Adopt International Financial Reporting Standards as of March 2014
March 1, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…